TCT 2021 | TCT 2021: narsoplimab in TA-TMA

Name: TCT 2021: narsoplimab in TA-TMA
Uploaded: 2021-02-02T00:00:00Z
Duration: 2 min 44 s

Eleni Gavriilaki • 2 Feb 2021

TCT 2021

Eculizumab Narsoplimab

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, outlines studies to be presented at this year’s Transplantation & Cellular Therapy (TCT) meeting evaluating the use of narsoplimab, a MASP-2 inhibitor, in patients with transplant-associated thrombotic microangiopathy (TA-TMA). Dr Gavriilaki highlights two abstracts, the first evaluates the use of narsoplimab in eculizumab-refractory TA-TMA patients, and the second presents the results of an open-label study evaluating the efficacy of narsoplimab in adult patients with TA-TMA. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.